CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights

Rhea-AI Summary

CytoSorbents (NASDAQ: CTSO) will report its second quarter 2026 financial results and recent business highlights after market close on Thursday, August 6, 2026. Management will host a live conference call, webcast, and Q&A at 4:30 PM ET the same day.

The live webcast will be accessible at https://app.webinar.net/v62381bx4na, with an archived recording available later in the Investor Relations section of the company’s website. CytoSorbents develops blood purification technologies for critical care and cardiac surgery, including the CytoSorb and investigational DrugSorb-ATR systems.

Market reaction after 2Q26 earnings report: CTSO +5.58% in the Jul 20 session

+5.58%

2 alerts

+5.58% Session close to close

+5.3% Peak Tracked

$22.62M Market Cap

0.7x Rel. Volume

In the Jul 20 session, CTSO gained 5.58%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.3% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.6% in the session following this news. 100,000 shares were purchased by CFO Peter...

Analysis

The stock moved +5.6% in the session following this news. 100,000 shares were purchased by CFO Peter J. Mariani on June 15, 2026, according to the Form 4 record. A strong positive response would place the scheduled Q2 report against recent insider net buying, while the July 6 Nasdaq compliance notice remains a sourced risk.

Key Figures

Reporting date: August 6, 2026 Conference call time: 4:30 PM ET Countries distributed: over 70 countries +2 more

5 metrics

Reporting date August 6, 2026 Second quarter 2026 financial results

Conference call time 4:30 PM ET August 6, 2026

Countries distributed over 70 countries CytoSorb distribution

Cumulative devices used more than 300,000 devices CytoSorb devices used to date

Breakthrough Device Designations two FDA Breakthrough Device Designations DrugSorb-ATR

Previous Earnings date Reports

2 past events · Latest: Apr 30 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Q1 earnings date	Neutral	-4.0%	Scheduled Q1 2026 results and webcast details announced for May 13.
Mar 05	FY earnings date	Neutral	+1.9%	Scheduled Q4 and full-year 2025 results and webcast details announced for March 25.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Comparable earnings-date announcements produced mixed reactions of -4.04% and +1.91%, averaging -1.06%.

Key Terms

continuous renal replacement therapy, extracorporeal membrane oxygenation, emergency use authorization, breakthrough device designations, +2 more

6 terms

continuous renal replacement therapy medical

"dialysis, continuous renal replacement therapy or CRRT"

A hospital procedure that continuously filters a patient’s blood over many hours to replace the work of failing kidneys, similar to a slow, ongoing water purifier for the body. It matters to investors because demand, pricing and reimbursement for the machines, consumable supplies and related drugs affect revenues and costs for medical device makers, hospitals and suppliers tied to critical care and dialysis markets.

extracorporeal membrane oxygenation medical

"extracorporeal membrane oxygenation or ECMO"

A life-support technique that temporarily pumps a patient’s blood through an external machine to add oxygen and remove carbon dioxide, acting like an artificial lung when the patient’s own lungs or heart can’t function. Investors care because its use drives demand for specialized medical devices, trained staff and hospital capacity, influences treatment costs and reimbursement, and can materially affect revenue and risk for device makers, hospitals and healthcare suppliers.

emergency use authorization regulatory

"received FDA Emergency Use Authorization in the United States"

A regulatory emergency use authorization allows a government health agency to temporarily permit the use or sale of a medical product—such as a vaccine, test, or treatment—before full formal approval when there is a public health crisis. For investors, an authorization can rapidly open revenue and market access while carrying higher regulatory and demand risk, like a fast-track pass that speeds a product to customers but may still require further review and can affect a company's valuation and future sales prospects.

breakthrough device designations regulatory

"received two FDA Breakthrough Device Designations"

A breakthrough device designation is a regulatory label granted to certain medical devices that show potential to provide more effective diagnosis or treatment for serious conditions. It signals that regulators will offer accelerated review, more frequent interaction, and flexible trial pathways—like giving a complex product a fast lane through paperwork and testing. Investors pay attention because the designation can shorten time to market and reduce approval risk, affecting a company’s development timeline and valuation.

direct oral anticoagulants medical

"direct oral anticoagulants (DOAC) apixaban and rivaroxaban"

Direct oral anticoagulants are prescription drugs taken by mouth that reduce the blood’s ability to form clots, used to prevent strokes and dangerous clots in conditions like irregular heartbeat or after certain surgeries. For investors, they matter because approval, safety data, patent protection, and competitive pricing directly affect sales and liability risk—similar to how a new, safer brake design can reshape demand and market share in the auto industry.

ce mark regulatory

"launched in the European Union under CE mark"

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., July 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business highlights after the market close on Thursday, August 6, 2026.

CytoSorbents' management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30PM ET the same day. 

Conference Call and Webcast Details:
Date: Thursday, August 6, 2026
Time: 4:30 PM ET
Live webcast link: https://app.webinar.net/v62381bx4na

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.

An archived recording of the conference call will be available under the Investor Relations section of the Company's website at https://ir.cytosorbents.com/

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date. CytoSorb® was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb® has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb® is not yet approved or cleared in the United States.

In the U.S. and Canada, CytoSorbents is developing the DrugSorb®-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb®, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.

The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb®, ContrastSorb, and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/ and follow us on Facebook and X and LinkedIn. 

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, the impact of geopolitical events including the recent war in Iran, our ability to successfully obtain U.S. FDA and Health Canada regulatory approval and marketing authorization, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve operating cash-flow break-even in the second half of 2026, our ability to appropriately finance the Company, including our ability to meet our financial obligations and comply with the covenants under our existing debt agreement,, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and X

U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
ir@cytosorbents.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-report-second-quarter-2026-financial-results-and-recent-business-highlights-302829327.html

SOURCE Cytosorbents Corp

FAQ

When will CytoSorbents (NASDAQ: CTSO) report its Q2 2026 financial results?

CytoSorbents will report its Q2 2026 financial results on Thursday, August 6, 2026, after market close. According to CytoSorbents, the release will be followed by a management conference call and webcast at 4:30 PM ET the same day.

How can investors listen to the CytoSorbents (CTSO) Q2 2026 earnings conference call?

Investors can listen to the CytoSorbents Q2 2026 call via a live webcast at https://app.webinar.net/v62381bx4na. According to CytoSorbents, the call starts at 4:30 PM ET on August 6, 2026, with an archived recording later on the Investor Relations website.

Will a replay of the CytoSorbents (CTSO) Q2 2026 earnings call be available?

Yes, a replay will be available. According to CytoSorbents, an archived recording of the August 6, 2026 conference call will be posted in the Investor Relations section of the company’s website, allowing investors to review the discussion after the live event.

What does CytoSorbents (CTSO) specialize in within the medical device sector?

CytoSorbents specializes in blood purification technologies for intensive care and cardiac surgery. According to CytoSorbents, its polymer bead-based cartridges, including CytoSorb, are designed to remove inflammatory agents, toxins, and certain drugs from blood using standard hospital blood pump systems.

What is CytoSorb, the lead product of CytoSorbents (NASDAQ: CTSO)?

CytoSorb is a blood purification cartridge used to remove cytokines, toxins, and certain drugs from blood. According to CytoSorbents, it is approved in the European Union, distributed in over 70 countries, and has been used in more than 300,000 treatments to date.

What is DrugSorb-ATR being developed by CytoSorbents (CTSO) and what is its regulatory status?

DrugSorb-ATR is an investigational antithrombotic removal system for high-risk surgeries in the U.S. and Canada. According to CytoSorbents, it has received two FDA Breakthrough Device Designations but is not yet approved in either country, with regulatory approval actively being pursued.